Actor James Nelson-Joyce is remembered for starring as James Yates in Little Blue Boy, Johnno in Time, Spider in The Outlaws ...

A Thousand Blows season two is dropping this week, taking Disney+ fans back into the world of Peaky Blinders creator Steven ...

Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...

Braveheart is set to leave Prime Video on January 1, meaning viewers are running out of time to revisit one of the most ...

The Scottish war epic starring Chris Pine has left viewers raving, with some praising its 'attention to detail' and even ...

Netflix fans are urged to watch the ‘epic' war film viewers say is ‘much more historically accurate' than Braveheart.

Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust with big names in an emerging heart disease drug arena. Backed by ...

Board to include Chris Viehbacher as Chair, with investor syndicate led by Andreessen Horowitz, Forbion, and OrbiMed with participation from Enavate Sciences (a platform of Patient Square Capital) and ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s one of the largest ...